Breast cancer and cancer stem cells: A mini-review

Tumori

Volumn 100, Issue 4, 2014, Pages 363-369

  Filipova, Alzbeta ^a   Seifrtova, Martina ^a   Mokry, Jaroslav ^a   Dvorak, Josef ^a   Rezacova, Martina ^a   Filip, Stanislav ^a   Diaz Garcia, Daniel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Cancer stem cells; Metastasis; Niche

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALPHA6 INTEGRIN; BRCA1 PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CELL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; CXCL7 CHEMOKINE; HERMES ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; NOTCH RECEPTOR; SMAD3 PROTEIN; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; TUMOR MARKER;

BREAST CANCER; CANCER MODEL; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL RENEWAL; CYTOKINE PRODUCTION; HUMAN; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; AXILLA; BREAST TUMOR; DRUG RESISTANCE; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; PATHOLOGY; PROGNOSIS;

AXILLA; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908220535     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1636.17886     Document Type: Review

References (94)

1. Gaffan J, Dacre J, Jones A: Educating undergraduate medical students about oncology: A literature review. J Clin Oncol, 24: 1932-1939, 2006.
2. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin, 60: 277-300, 2010.
3. Desantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin, 61: 409-418, 2011.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893-2917, 2010.
5. Pierce G: Neoplasms, differentiations and mutations. Am J Pathol, 77: 103-118, 1974.
6. O'Brien CA, Kreso A, Jamieson CH: Cancer stem cells and self-renewal. Clin Cancer Res, 16: 3113-3120, 2010.
7. Al-Hajj M, Clarke M: Self-renewal and solid tumor stem cells. Oncogene, 23: 7274-7282, 2004.
8. Dick JE: Breast cancer stem cells revealed. Proc Natl Acad Sci USA, 100: 3547-3549, 2003.
9. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100: 3983-3988, 2003.
10. Hirschmann-Jax C, Foster A, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA: A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA, 101: 14228-14233, 2004.
11. Smalley M, Ashworth A: Stem cells and breast cancer: A field in transit. Nat Rev Cancer, 3: 832-844, 2003.
12. Wang J, Cao MG, You CZ, Wang CL, Liu SL, Kai C, Dou J: A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Cell Mol Biol (Noisy-le-grand), 58: OL1641-1645, 2012.
13. Petersen OW, Polyak K: Stem cells in the human breast. Cold Spring Harb Perspect Biol, 2: A003160, 2011.
14. Takebe N, Ivy SP: Controversies in cancer stem cells: Targeting embryonic signaling pathways. Clin Cancer Res, 16: 3106-3112, 2010.
15. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138: 645-659, 2009.
16. Park CY, Tseng D, Weissman IL: Cancer stem cell-directed therapies: Recent data from the laboratory and clinic. Mol Ther, 17: 219-230, 2009.
17. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J, Burchell JM: Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res, 10: R52, 2008.
18. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP: Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 140: 62-73, 2010.
19. Goodell M, Brose K, Paradis G, Conner A, Mulligan R: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med, 183: 1797-1806, 1996.
20. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1: 555-567, 2007.
21. Alison MR, Guppy NJ, Lim SML, Nicholson LJ: Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J Pathol, 222: 335-344, 2010.
22. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res, 10: R10, 2008.
23. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med, 15: 907-913, 2009.
24. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 100: 672-679, 2008.
25. Phillips TM, McBride WH, Pajonk F: The response of CD24(-/low)/CD44+ breast cancer initiating cells to radiation. J Natl Cancer Inst, 98: 1777-1785, 2006.
26. Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F: Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res, 12: R13, 2010.
27. Trumpp A, Wiestler OD: Mechanisms of disease: Cancer stem cells -targeting the evil twin. Nat Clin Pract Oncol, 5: 337-347, 2008.
28. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458: 780-783, 2009.
29. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA, 104: 618-623, 2007.
30. Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, Poggi A, Cappelli E, Zona G, Spaziante R, Corte G, Frosina G: Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res, 7: 383-392, 2009.
31. Ding XW, Wu JH, Jiang CP: ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci, 86: 631-637, 2010.
32. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 95: 15665-15670, 1998.
33. Ni Z, Bikadi Z, Rosenberg MF, Mao Q: Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab, 11: 603-617, 2010.
34. Charafe-Jauff ret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res, 69: 1302-1313, 2009.
35. Rosen JM, Jordan CT: The increasing complexity of the cancer stem cell paradigm. Science, 324: 1670-1673, 2009.
36. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL, Wahl GM: Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res, 66: 9339-9344, 2006.
37. Moore KA, Lemischka IR: Stem cells and their niches. Science, 311: 1880-1885, 2006.
38. LaBarge MA: The difficulty of targeting cancer stem cell niches. Clin Cancer Res, 16: 3121-3129, 2010.
39. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res, 6: R605-R615, 2004.
40. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res, 66: 6063-6071, 2006.
41. Liu S, Dontu G, Wicha MS: Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res, 7: 86-95, 2005.
42. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature, 434: 843-850, 2005.
43. Huang CL, Liu D, Ishikawa S, Nakashima T, Nakashima N, Yokomise H, Kadota K, Ueno M: Wnt1 overexpression promotes tumour progression in nonsmall cell lung cancer. Eur J Cancer, 44: 2680-2688, 2008.
44. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A, Feldmann G: Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res, 15: 2291-2301, 2009.
45. Prosperi JR, Goss KH: A Wnt-ow of opportunity: Targeting the Wnt/betacatenin pathway in breast cancer. Curr Drug Targets, 11: 1074-1088, 2010.
46. Nusse R: Wnt signaling in disease and in development. Cell Res, 15: 28-32, 2005.
47. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA, 97: 4262-4266, 2000.
48. Massague J: TGFbeta in cancer. Cell, 134: 215-230, 2008.
49. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer, 9: 265-273, 2009.
50. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133: 704-715, 2008.
51. Yang J, Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell, 14: 818-829, 2008.
52. Ikenouchi J, Matsuda M, Furuse M, Tsukita S: Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci, 116: 1959-1967, 2003.
53. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF, Fuxe J: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol, 11: 943-950, 2009.
54. Kelleher FC, Fennelly D, Rafferty M: Common critical pathways in embryogenesis and cancer. Acta Oncol, 45: 375-388, 2006.
55. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449: 557-563, 2007.
56. Morrissey C, Vessella RL: The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem, 101: 873-886, 2007.
57. Haynesworth SE, Baber MA, Caplan AI: Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-1 alpha. J Cell Physiol, 166: 585-592, 1996.
58. Kadereit S, Deeds LS, Haynesworth SE, Koc ON, Kozik MM, Szekely E, Daum-Woods K, Goetchius GW, Fu P, Welniak LA, Murphy WJ, Laughlin MJ: Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer. Stem Cells, 20: 573-582, 2002.
59. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLOS ONE, 4: E4992, 2009.
60. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group: Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res, 63: 3560-3566, 2003.
61. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLOS ONE, 3: E3077, 2008.
62. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS: Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res, 71: 614-624, 2011.
63. Kalwitz G, Endres M, Neumann K, Skriner K, Ringe J, Sezer O, Sittinger M, Häupl T, Kaps C: Gene expression profile of adult human bone marrow derived mesenchymal stem cells stimulated by the chemokine CXCL7. Int J Biochem Cell Biol, 41: 649-658, 2009.
64. Tang Z, Yu M, Miller F, Berk RS, Tromp G, Kosir MA: Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg, 196: 690-696, 2008.
65. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H: CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res, 8: R59, 2006.
66. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest, 120: 485-497, 2010.
67. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest, 117: 3988-4002, 2007.
68. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS: Aldehyde dehydrogenase 1 positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res, 16: 45-55, 2010.
69. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicinbased chemotherapy for breast cancers. Clin Cancer Res, 15: 4234-4241, 2009.
70. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK: CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res, 70: 4624-4633, 2010.
71. Ibrahim SF, Diercks AH, Petersen TW, van den Engh G: Kinetic analyses as a critical parameter in defining the side population (SP) phenotype. Exp Cell Res, 313: 1921-1926, 2007.
72. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med, 7: 1028-1034, 2001.
73. Alvi A, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco Md, Dale T, Smalley M: Functional and molecular characterization of mammary side population cells. Breast Cancer Res, 5: R1-R8, 2003.
74. Patrawala, L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res, 65: 6207-6219, 2005.
75. Steiniger SCJ, Coppinger JA, Kruger JA, Yates J III, Janda KD: Quantitative mass spectrometry identifies drug targets in cancer stem cell containing side population. Stem Cells, 26: 3037-3046, 2008.
76. Christgen M, Ballmaier M, Bruchhardt H, von Wasielewski R, Kreipe H, Lehmann U: Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem, 306: 201-212, 2007.
77. Clayton H, Titley I, Vivanco M: Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res, 297: 444-460, 2004.
78. Clarke RB, Spence K, Anderson E, Howell A, Okano H, Potten CS: A putative human breast stem cell population is enriched for steroid receptor-positive cells. Develop Biol, 277: 443-456, 2005.
79. Nakshatri H, Srour E, Badve S: Breast cancer stem cells and intrinsic subtypes: Controversies rage on. Curr Stem Cell Res Ther, 4: 50-60, 2009.
80. Karrison TG, Ferguson DJ, Meier P: Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst, 91: 80-85, 1999.
81. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA: From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA, 100: 7737-7742, 2003.
82. Kakarala M, Wicha MS: Implication of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol, 26: 2813-2820, 2008.
83. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100: 8418-8423, 2003.
84. Rosen PP, Groshen S, Kinne DW, Norton L: Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol, 11: 2090-2100, 1993.
85. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24, 740 breast cancer cases. Cancer, 63: 181-187, 1989.
86. Lianidou ES, Markou A: Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin Chem, 57: 1242-1255, 2011.
87. Rack B, Janni W, Gerber B, Strobl B, Schindelbeck C, Klanner E, Rammel G, Sommer H, Dimpfl T, Friese K: Patients with recurrent breast cancer: Does the primary axillary lymph node status predict more aggressive tumor progression? Breast Cancer Res Treat, 82: 83-92, 2003.
88. Padína-Iruegas ME, López López R: Stem cells as a tool for breast imaging. J Oncol, 2012: 814014, 2012.
89. Hashimoto K, Shinizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K: Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome. Oncology, 82: 168-174, 2012.
90. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH: CF44(+)/CD22(-low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol, 43: 364-373, 2012.
91. Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer, 93: 1046-1052, 2005.
92. Ross JS: Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Ady Anat Pathol, 16: 204-215, 2009.
93. Malhotra GK, Zhao X, Band H, Band V: Shared signaling pathways in normal and breast cancer stem cells. J Carcinog, 10: 38, 2011.
94. Guo SM, Liu M, Gonzalez-Perez RR : Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophysis Acta, 1815: 197-213, 2011.